NICE recommends digital tech for ADHD diagnosis in children and young people
July 16, 2024Medical Communications ADHD, Diagnostics, NICE
The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …
AI-powered prognosis test company Spotlight Medical secures €6.2m in seed funding
July 15, 2024Research and Development Oncology, Precision Medicine, Spotlight Medical, artificial intelligence, oncology, seed funding
Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. …
ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models
July 15, 2024Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug
Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …
Pfizer selects once-daily obesity drug for advancement
July 12, 2024Research and Development Obesity, Pfizer Inc, clinical trials, obesity
Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …
Imidex and Spesana collaborate over impact of AI in lung nodule and mass detection
July 12, 2024Research and Development Imidex, Oncology, Spesana, artificial intelligence, cancer detection, lung cancer
Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …
Aspect Biosystems announces partnership with governments of Canada and British Columbia
July 11, 2024Business Services Aspect Biosciences, Pharmacy, government, investment
Aspect Biosystems has announced that it has entered into an agreement with the governments of Canada and British Columbia, under …
Biophytis gains IND approval from FDA for obesity study
July 11, 2024Medical Communications Biophytis, IND, Obesity, clinical trial, obesity
Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …
Pharmaxo acquired by Icon Group in strategic partnership
July 10, 2024Business Services Oncology, Pharmaxo, acquisition, strategic parnership
Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global …
Certara to acquire Chemaxon for drug discovery portfolio
July 10, 2024Business Services Certara, Chemaxon, Pharmacy, acquisition, drug discovery
Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara will acquire Chemaxon. The deal …
iOnctura expands clinical trial programme for NSCLC
July 9, 2024Research and Development NSCLC, Oncology, clinical trial, iOnctura, lung cancer
iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.
Roche gains CE Mark for AI glucose monitoring system for diabetes management
July 9, 2024Medical Communications AI, Diabetes, Roche, diabetes, glucose monitoring
Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.
Oxolife shares data from phase 2 trial for infertility drug
July 8, 2024Research and Development Oxolife, Reproductive health, clinical trial, infertility
Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction …
AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment
July 8, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …
GSK and CureVac to restructure collaboration into licensing agreement
July 3, 2024Sales and Marketing CureVac, GSK, Immunology, License Agreement, collaboration
GSK and CureVac have announced that they have restructured their existing collaboration into a license agreement, which is intended to …
Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment
July 3, 2024Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …
Arcturus Therapeutics provides update on OTC deficiency and CF programmes
July 2, 2024Research and Development Arcturus Therapeutics, OTC, Pharmacy, clinical trials, cystic fibrosis
Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, …
NeuroSense shares update from ALS treatment trial
July 2, 2024Research and Development NeuroSense, Neurology, als, clinical trial
NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …
Sanofi shares results from phase 2 trial for frexalimab in MS treatment
July 1, 2024Research and Development MS, Neurology, Sanofi, multiple sclerosis
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
July 1, 2024Research and Development COVID-19, EMA, Infections and infestations, coronavirus
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
June 28, 2024Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
